32885-82-8

Usage

Uses

Used in Pharmaceutical Industry:
De-O-Methyllasiodiplodin is used as a potential drug candidate for its potent biological properties. De-O-Methyllasiodiplodin's ability to interact with various biological systems makes it a valuable asset in the development of new therapeutic agents.
Used in Medical Research:
De-O-Methyllasiodiplodin is used as a subject of study in medical research to explore its potential applications in treating various diseases. Its unique chemical composition and biological activity provide a foundation for investigating its efficacy and safety in clinical settings.
Used in Drug Development:
De-O-Methyllasiodiplodin is used as a key component in the development of new drugs. Its potent biological properties suggest that it may play a crucial role in the creation of novel therapeutics that could address unmet medical needs.
Note: Since the provided materials do not specify the exact applications or industries where De-O-Methyllasiodiplodin is used, the uses listed above are based on the general potential of biological compounds with potent properties. Further research and information would be required to provide more specific applications.

Upstream product

• 125590-95-6 (+)-(R)-12,14-dimethoxy-3-methyl-3,4,5,6,7,8,9,10-octahydro-1H-benzo[c][1]oxacyclododecin-1-one 
• 539-87-7 oxocan-2-one 
• 6110-37-8 methyl 2,4-dimethoxy-6-methylbenzoate 
• 38315-25-2 methyl 7-iodoheptanoate 
• 14565-11-8 methyl 7-hydroxyheptanoate 
• 7149-90-8 2,4-dimethoxy-6-methyl-benzaldehyde 
• 3686-57-5 2,4-dimethoxy-6-methylbenzoic acid 
• 125520-74-3 (R)-6-(8'-Hydroxynonyl)-2,4-dimethoxybenzoesaeure-methylester 
• 125520-73-2 (-)(R) 2,4-dimethoxy-6-(8-hydroxynonyl) benzoic acid 
• 130877-73-5 methyl 2,4-dimethoxy-6-(7-methoxycarbonyl) heptyl benzoate 
• 130877-74-6 methyl 2,4-dimethoxy-6-(p-tolylsulfonyl) methyl benzoate 
• 130877-72-4 (+)(R) methyl 3,5-dimethoxy-6-<8-oxo-9-(p-tolylsulfinyl) nonyl> benzoate 
• 130877-75-7 methyl 2,4-dimethoxy-6-<1-(p-tolylsulfonyl)-7-methoxycarbonyl heptyl> benzoate 
• 130877-76-8 methyl 2,4-dimethoxy-6-(p-tolylsulfinyl) methyl benzoate 

Downstream Products

• 1276020-06-4 C₂₃H₂₈O₄ 
• 1276020-13-3 C₃₀H₃₀O₆ 
• 1276020-17-7 C₃₀H₂₈Cl₂O₆ 
• 1276020-19-9 C₃₀H₃₄O₈S₂ 
• 1276020-15-5 C₃₀H₂₈Br₂O₆ 
• 1276020-08-6 C₃₀H₃₂N₂O₈ 

Relevant academic research and scientific papers

A Short and Efficient Approach for the Total Synthesis of (S)-Zearalenone and (R)-De-O-methyllasiodiplodin by Using Stille and RCM Protocols

A concise, flexible, and linear approach has been devised for the total synthesis of the resorcinylic acid lactones (S)-zearalenone (2) and (R)-de-O-methyllasiodiplodin (4) by using a Stille cross-coupling strategy. The other key steps of the synthesis include a ring-closing metathesis (RCM), a chemoselective reduction of an α,β-unsaturated ketone, and a transesterification reaction.

Synthesis, modification, and evaluation of (R)-de-O-methyllasiodiplodin and analogs as nonsteroidal antagonists of mineralocorticoid receptor

Macrolide (R)-de-O-methyllasiodiplodin (1), discovered to be a potent nonsteroidal antagonist of the mineralocorticoid receptor (MR), was synthesized via an efficient method and evaluated for MR antagonistic activity together with its analogs. Among all the tested compounds, compounds 18a, 18b and 18c, exhibited more potent antagonistic activity against MR with IC50 values ranging from 0.58 to 1.11 μM. Generally, it was obviously demonstrated that acetylation at phenolic hydroxyl groups and the ring size in analogs of 1 were very important for MR antagonist activity.

Asymmetric synthesis of orsellinic acid type macrolides: The example of lasiodiplodin

The asymmetric synthesis of both enantiomers of methyl lasiodiplodin is described. The chiral centers were created in the very last steps of the synthesis by asymmetric induction of a chiral sulfoxide group.